GSK Plc had earlier sued the US Food and Drug Administration for clearing the sale of a generic form of Flonase. The company alleged that the FDA failed to establish that the generic copy of Flonase worked the same way as the original nasal spray.
The FDA in the second week of February had approved the generic companies' applications to sell the generic version. Following this, the GSK sought a stay order form the US Court against the FDA decision. Cipla is learnt to have started shipping the product after the US FDA clearance.
The US market for the drug is pegged at $1 billion. Cipla has been selling the product in the European market. It had won a similar case in the UK against GSK a couple of years ago.